The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Taking control

Authors:

Zaharov V.V.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2024;(12): 26‑37

Read: 244 times

Buy for 300₽
Contact the author
Table of contents

To cite this article:

Zaharov VV. Taking control. Non Nocere. New Therapeutic Journal. 2024;(12):26‑37. (In Russ.)

 
ЭндоКард
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Abstract:

Cognitive impairment in patients with arterial hypertension.

Authors:

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Close metadata

References:

  1. Kobalava Zh.D., Konradi A.O., Nedogoda S.V. et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3-3786
  2. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-3104. https://doi.org/10.1093/eurheartj/ehy339
  3. Boytsov S.A., Balanova Yu.A., Shalnova S.A. et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.) https://doi.org/10.15829/1728-8800-2014-4-4-14
  4. Meissner A. Hypertension and the Brain: A Risk Factor for More Than Heart Disease. Cerebrovasc Dis. 2016;42(3-4):255-62.  https://doi.org/10.1159/000446082
  5. Iadecola C, Gottesman RF. Neurovascular and Cognitive Dysfunction in Hypertension. Circ Res. 2019;124(7):1025-1044. https://doi.org/10.1161/CIRCRESAHA.118.313260
  6. Lei C, Deng Q, Li H, Zhong L. Association Between Silent Brain Infarcts and Cognitive Function: A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis. 2019;28(9):2376-2387. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.03.036
  7. Qiu C, Cotch MF, Sigurdsson S, et al. Cerebral microbleeds, retinopathy, and dementia: the AGES-Reykjavik Study. Neurology. 2010;75(24):2221-2228. https://doi.org/10.1212/WNL.0b013e3182020349
  8. LADIS Study Group. 2001-2011: a decade of the LADIS (Leukoaraiosis And DISability) Study: what have we learned about white matter changes and small-vessel disease? Cerebrovasc Dis. 2011;32(6):577-588.  https://doi.org/10.1159/000334498
  9. Yakhno N.N., Levin O.S., Damulin I.V. Comparison of clinical and MRI data in dyscirculatory encephalopathy. Message 2: cognitive disorders. Journal of Neurology. 2001b;6(3):10. 
  10. Schmidt R, Schmidt H, Haybaeck J, et al. Heterogeneity in age-related white matter changes. Acta Neuropathol. 2011;122(2):171-185.  https://doi.org/10.1007/s00401-011-0851-x
  11. Smith EE, O’Donnell M, Dagenais G, et al. Early cerebral small vessel disease and brain volume, cognition, and gait. Ann Neurol. 2015;77(2):251-261.  https://doi.org/10.1002/ana.24320
  12. Duering M, Biessels GJ, Brodtmann A, et al. Neuroimaging standards for research into small vessel disease-advances since 2013. Lancet Neurol. 2023 Jul;22(7):602-618.  https://doi.org/10.1016/S1474-4422(23)00131-X
  13. Wardlaw JM, Makin SJ, Valdés Hernández MC, et al. Blood-brain barrier failure as a core mechanism in cerebral small vessel disease and dementia: evidence from a cohort study. Alzheimers Dement. 2017;13(6):634-643.  https://doi.org/10.1016/j.jalz.2016.09.006
  14. Hughes TM, Sink KM. Hypertension and Its Role in Cognitive Function: Current Evidence and Challenges for the Future. Am J Hypertens. 2016;29(2):149-157.  https://doi.org/10.1093/ajh/hpv180
  15. Langbaum JB, Chen K, Launer LJ, et al. Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging. 2012;33:827.e11-827.e19.  https://doi.org/10.1016/j.neurobiolaging.2011.06.020
  16. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer’s disease. The Nun Study. JAMA. 1997;277(10):813-817.  https://doi.org/10.1001/jama.1997.03540340047031
  17. Kulesh AA, Emelin AY, Bogolepova AN et al. Clinical manifestations and issues of diagnosis of chronic cerebrovascular disease (chronic cerebral ischemia) at an early (pre-dementia) stage. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):4-12. (In Russ.) https://doi.org/10.14412/2074-2711-2021-1-4-12
  18. Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21(1):49-55.  https://doi.org/10.1016/s0197-4580(00)00096-8
  19. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ. 2001;322(7300):1447-14451. https://doi.org/10.1136/bmj.322.7300.1447
  20. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347(9009):1141-1145. https://doi.org/10.1016/s0140-6736(96)90608-x
  21. Elias MF, Wolf PA, D’Agostino RB, Cobb J, White LR. Untreated blood pressure level is inversely related to cognitive functioning: The Framingham Study. Am J Epidemiol. 1993;138(6):353-364.  https://doi.org/10.1093/oxfordjournals.aje.a116868
  22. Kim H, Ang TFA, Thomas RJ, Lyons MJ, Au R. Long-term blood pressure patterns in midlife and dementia in later life: Findings from the Framingham Heart Study. Alzheimers Dement. 2023;19(10):4357-4366. https://doi.org/10.1002/alz.13356
  23. Starchina YA, Zakharov VV. Cognitive impairment in hypertension. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):113-118. (In Russ.) https://doi.org/10.14412/2074-2711-2021-1-113-118
  24. Vakhnina N. Vascular cognitive impairment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(1):74-79. (In Russ.) https://doi.org/10.14412/2074-2711-2014-1-74-79
  25. Sachdev P, Kalaria R, O’Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-218.  https://doi.org/10.1097/WAD.0000000000000034
  26. Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014 Nov;10(6):844-852.  https://doi.org/10.1016/j.jalz.2014.01.001
  27. Yakhno N.N., Zakharov V.V., Koberskaya N.N. et al. “Premeditated” (subjective and mild) cognitive disorders. Journal of Neurology. 2017;22(4):198-204. 
  28. Lokshina A.B., Zakharov V.V., Grishina D.A. et al. Heterogeneity of moderate cognitive impairment syndrome (analysis of the work of specialized outpatient reception). Neurology, Neuropsychiatry, Psychosomatics. 2021;13(3):34-41. 
  29. Yakhno N.N. Cognitive disorders in the neurological clinic. Neurological Journal. 2006;11(Suppl. 1):4-12. 
  30. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for 248 dementia: Validation in a population-based sample. J Am Geriatr Soc. 2003;51:1451-1454. https://doi.org/10.1046/j.1532-5415.2003.51465.x
  31. Folstein M.F., Folstein S.E., McHugh P.R. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. Journal of psychiatric research. 1975; 12(3):189-198.  https://doi.org/10.1016/0022-3956(75)90026-6
  32. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.  https://doi.org/10.1111/j.1532-5415.2005.53221.x
  33. Martynov A.I., Tanashyan M.M., Malyavin A.G. et al. Resolution of the Council of Experts “Possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive impairment”. Therapy. 2023;9(10):148-158. 
  34. Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Duration of antihypertensive drug use and risk of dementia: A prospective cohort study. Neurology. 2009;72(20):1727-1734. https://doi.org/10.1212/01.wnl.0000345062.86148.3f
  35. Peila R, White LR, Masaki K, Petrovitch H, Launer LJ. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke. 2006 May;37(5):1165-1170. https://doi.org/10.1161/01.STR.0000217653.01615.93
  36. Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol. 2003 Feb;60(2):223-228.  https://doi.org/10.1001/archneur.60.2.223
  37. Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging. 2001 May-Jun;22(3):407-412.  https://doi.org/10.1016/s0197-4580(00)00241-4
  38. Shchulkin AV. A modern concept of antihypoxic and antioxidant effects of mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12-2):87-93. (In Russ.) https://doi.org/10.17116/jnevro201811812287
  39. Fedin AI, Zaharov VV, Tanashyan MM et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):7-16. (In Russ.) https://doi.org/10.17116/jnevro20211211117
  40. Zakharov V.V., Ostroumova O.D., Kochetkov A.I., Klepikova M.V., Fedin A.I. International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol® and Mexidol® FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension. Therapy. 2023;9(1):145-159.  https://doi.org/10.18565/therapy.2023.1.145-159
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.